Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Tg Therapeutics Trial Site
Sarasota, Florida, United States
- Tg Therapeutics Trial Site
Hackensack, New Jersey, United States
- Tg Therapeutics Trial Site
New York, New York, United States
- Tg Therapeutics Trial Site
Durham, North Carolina, United States
- Tg Therapeutics Trial Site
Cincinnati, Ohio, United States
- Tg Therapeutics Trial Site
Nashville, Tennessee, United States
- Tg Therapeutics Investigational Trial Site
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Jan 2013
- Primary completion
- 28 Feb 2018
- Completion
- 28 Feb 2018
- Last update posted
- 23 Aug 2021
- Registered enrollment
- 90
- Registry id
- NCT01767766
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.